Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 212

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 212
---
, the
Sponsor deposited $22,600 in the Trust Account in connection with the extension of the business combination deadline. On January 4, 2024,
we made a series of payments of an aggregate of $128,133 to holders of redeemed Class A Common Stock (an aggregate of $11.02 per redeemed
share).

On February 5, 2024, the
parties entered into Amendment No. 1 to the Business Combination Agreement to, among other things, (i) remove the minimum cash condition,
(ii) modify the stock-price based milestones such that (a) the trading price condition for the First Level Earnout Target (as defined
in the Business Combination Agreement) shall be reset from $12.50 to 125% of the conversion price of the Series A Preferred Stock upon
the reset of such conversion price and (b) the trading price condition for the Second Level Earnout Target shall be reset from $15.00
to 150% of the conversion price of the Series A Preferred Stock upon reset of such conversion price, and (iii) increase the aggregate
number of shares of Class A Common Stock issuable to the stockholders of CERo in connection with the Business Combination from 4,651,704
shares to 5,000,000 shares. Such number of shares is in addition to up to 1,200,000 shares issuable upon satisfaction of certain earn-out
conditions and 382,651 shares issuable upon exercise of rollover options or warrants.

On February 8, 2024, we
held a special meeting of stockholders (the “Fourth Special Meeting”). At the Fourth Special Meeting, our stockholders adopted
and approved: (i) the Business Combination Agreement, pursuant to which Merger Sub merged with and into Legacy CERo, with Legacy CERo
surviving the merger as a wholly-owned subsidiary of PBAX and approved the Business Combination and the other transactions and ancillary
documents contemplated by and required for the Business Combination; (ii) on a non-binding advisory basis, certain changes to the PBAX
Charter, including the name change to CERo Therapeutics Holdings, Inc., share authorizations, and others; (iii) the issuance of Class
A Common Stock to Legacy CERo Stockholders pursuant to the Business Combination Agreement; (iv) the election of five directors; and (v)
the 2024 Equity Incentive Plan and the 2024 Employee Stock Purchase